Dish of the day
Bould Capital readmitted to AIM changing name to Cizzle Biotechnology Holdings (CIZ.L). Cizzle Biotechnology is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is hi ....
18 Aug 2021
Small Cap Feast: 14/05/21
AssetCo PLC (ASTO:LON), 36.0 | Team Internet Group plc (TIG:LON), 153 | Helios Underwriting PLC (HUW:LON), 168 | MyCelx Technologies Corp. (MYX:LON), 54.5 | Physiomics Plc (PYC:LON), 1.2 | Sunrise Resources plc (SRES:LON), 0.0 | Velocity Composites Plc (VEL:LON), 37.5 | e-Therapeutics plc (ETXPF:OTC), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast: 14/05/21
AssetCo PLC (ASTO:LON), 36.0 | Team Internet Group plc (TIG:LON), 153 | Helios Underwriting PLC (HUW:LON), 168 | MyCelx Technologies Corp. (MYX:LON), 54.5 | Physiomics Plc (PYC:LON), 1.2 | Sunrise Resources plc (SRES:LON), 0.0 | Velocity Composites Plc (VEL:LON), 37.5 | e-Therapeutics plc (ETXPF:OTC), 0
- Published:
18 Aug 2021 - Author:
-
Pages:
2
Dish of the day
Bould Capital readmitted to AIM changing name to Cizzle Biotechnology Holdings (CIZ.L). Cizzle Biotechnology is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is hi ....